Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2010 Dec;3(12):1565–1570. doi: 10.1158/1940-6207.CAPR-10-0149

Table 3.

9cUAB30 pharmacokinetic parameters (n = 13)

Tmax,h Half-life, h Cmax, ng/mL AUC 0-inf,
ng/mL hr		 Cl, L/h V, L Clr, L/h
5 mga (n = 3) 3.12 ± 3.25 2.79 ± 0.80 46.9 ± 34.5 193 ±114 39.3 ± 34.3 138 ± 86.0 0.085 ± 0.050
10 mg (n = 6) 2.08 ± 1.02 5.76 ± 0.76 55.9 ± 39.4 318 ± 184 40.4 ± 19.7 337 ± 174 0.035 ± 0.049
20 mg (n = 4) 2.88 ± 1.31 7.21 ± 1.04 82.0 ± 9.77 827 ±196 25.1 ± 5.00 258 ± 49.0 0.232 ± 0.060
a

Most 9cUAB30 plasma concentrations were detectable, but below the limit of quantitation in 1 subject in the 5-mg dose cohort and this patient was excluded from analysis.